Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)

Market Cap	33.76B
Revenue (ttm)	2.82B
Net Income (ttm)	827.60M
Shares Out	406.80M
EPS (ttm)	2.03
PE Ratio	40.89
Forward PE	30.84
Dividend	0.41 (0.49%)
Ex-Dividend Date	May 23, 2024

Volume	2,493,247
Average Volume	2,317,095
Open	82.11
Previous Close	82.99
Day's Range	82.11 - 83.30
52-Week Range	46.30 - 88.38
Beta	0.45
RSI	57.02
Earnings Date	Mar 28, 2025

About Xiamen Amoytop Biotech

Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China. The company provides solutions for diseases, such as viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is based in Xiamen, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 1,960
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688278

Financial Performance

In 2024, Xiamen Amoytop Biotech's revenue was 2.82 billion, an increase of 34.13% compared to the previous year's 2.10 billion. Earnings were 827.60 million, an increase of 49.00%.